Contact this trialFirst, we need to learn more about you.
Virus Therapy
MEM-288 + Nivolumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Tampa, Florida
This trial is designed to find the maximum tolerated dose of MEM-288 monotherapy, and to see if the oncolytic effect of MEM-288 can provide a strong signal for dendritic cell-mediated T cell activation, leading to the generation of systemic anti-tumor T cell responses.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service